{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T08:25:44Z","timestamp":1770279944179,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"NSFC","doi-asserted-by":"crossref","award":["82304072"],"award-info":[{"award-number":["82304072"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16236-6","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T14:44:34Z","timestamp":1755701074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Concomitant anticoagulants and the survival of cancer patients treated with immune checkpoint inhibitors: a meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Jin","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"issue":"4","key":"16236_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The Blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12 (4), 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"issue":"7420","key":"16236_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature11489","volume":"490","author":"A Ribas","year":"2012","unstructured":"Ribas, A. & Tumeh, P. C. Cancer therapy: tumours switch to resist. Nature 490 (7420), 347\u2013348 (2012).","journal-title":"Nature"},{"issue":"18","key":"16236_CR3","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2217\/fon-2021-1647","volume":"18","author":"A Rizzo","year":"2022","unstructured":"Rizzo, A. et al. KEYNOTE-522, IMpassion031 and geparnuevo: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol. 18 (18), 2301\u20132309 (2022).","journal-title":"Future Oncol."},{"issue":"8","key":"16236_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2217\/fon-2020-0989","volume":"17","author":"AD Ricci","year":"2021","unstructured":"Ricci, A. D., Rizzo, A. & Brandi, G. DNA damage response alterations in gastric cancer: knocking down a new wall. Future Oncol. 17 (8), 865\u2013868 (2021).","journal-title":"Future Oncol."},{"key":"16236_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.clnesp.2025.03.023","volume":"68","author":"O Bas","year":"2025","unstructured":"Bas, O., Sahin, T. K., Karahan, L., Rizzo, A. & Guven, D. C. Prognostic significance of the cachexia index (CXI) in patients with cancer: A systematic review and meta-analysis. Clin. Nutr. ESPEN. 68, 240\u2013247 (2025).","journal-title":"Clin. Nutr. ESPEN"},{"key":"16236_CR6","doi-asserted-by":"crossref","unstructured":"Sahin, T. K., Ayasun, R., Rizzo, A. & Guven, D. C. Prognostic value of Neutrophil-to-Eosinophil ratio (NER) in cancer: A systematic review and Meta-Analysis. Cancers (Basel). 16(21), 3689 (2024).","DOI":"10.3390\/cancers16213689"},{"key":"16236_CR7","doi-asserted-by":"crossref","unstructured":"Vitale, E., Rizzo, A., Santa, K. & Jirillo, E. Associations between cancer risk. Inflamm. Metabolic Syndrome: Scoping Rev. Biology (Basel). 13(5), 352 (2024).","DOI":"10.3390\/biology13050352"},{"issue":"1","key":"16236_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu, M. et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 Blockade via combination therapy and PD-L1 regulation. J. Hematol. Oncol. 15 (1), 24 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"16236_CR9","doi-asserted-by":"crossref","unstructured":"Rizzo, A. & Ricci, A. D. Challenges and future trends of hepatocellular carcinoma immunotherapy. Int. J. Mol. Sci. 23(19), 11363 (2022).","DOI":"10.3390\/ijms231911363"},{"issue":"1","key":"16236_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.euo.2023.07.003","volume":"7","author":"M Santoni","year":"2024","unstructured":"Santoni, M. et al. Real-world outcome of patients with advanced renal cell carcinoma and Intermediate- or Poor-risk international metastatic renal cell carcinoma database consortium criteria treated by Immune-oncology combinations: differential effectiveness by risk group?? Eur. Urol. Oncol. 7 (1), 102\u2013111 (2024).","journal-title":"Eur. Urol. Oncol."},{"issue":"7","key":"16236_CR11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nrc1887","volume":"6","author":"CD Scripture","year":"2006","unstructured":"Scripture, C. D. & Figg, W. D. Drug interactions in cancer therapy. Nat. Rev. Cancer. 6 (7), 546\u2013558 (2006).","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"16236_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","volume":"22","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2020","unstructured":"Mu\u00f1oz Mart\u00edn, A. J. et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin. Transl Oncol. 22 (2), 171\u2013186 (2020).","journal-title":"Clin. Transl Oncol."},{"issue":"5","key":"16236_CR13","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s11912-023-01384-7","volume":"25","author":"MA Martins","year":"2023","unstructured":"Martins, M. A., Silva, T. F. & Fernandes, C. J. An update in anticoagulant therapy for patients with Cancer-Associated venous thromboembolism. Curr. Oncol. Rep. 25 (5), 425\u2013432 (2023).","journal-title":"Curr. Oncol. Rep."},{"key":"16236_CR14","doi-asserted-by":"crossref","unstructured":"Metelli, A. et al. Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-\u03b2. Sci. Transl Med. 12(525), eaay4860 (2020).","DOI":"10.1126\/scitranslmed.aay4860"},{"key":"16236_CR15","doi-asserted-by":"crossref","unstructured":"Graf, C. et al. Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. Sci. Immunol. 4(39), eaaw8405 (2019).","DOI":"10.1126\/sciimmunol.aaw8405"},{"key":"16236_CR16","doi-asserted-by":"crossref","unstructured":"Cortellini, A. et al. Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice. J. Immunother Cancer. 8(2), e001361 (2020).","DOI":"10.1136\/jitc-2020-001361"},{"issue":"1","key":"16236_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12967-021-02712-w","volume":"19","author":"P Johannet","year":"2021","unstructured":"Johannet, P. et al. Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients. J. Transl Med. 19 (1), 47 (2021).","journal-title":"J. Transl Med."},{"key":"16236_CR18","doi-asserted-by":"crossref","unstructured":"Nichetti, F. et al. Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events?? Mechanisms and impact in Non-Small cell lung cancer patients. Cancers (Basel): 12(1), 67 (2019).","DOI":"10.3390\/cancers12010067"},{"key":"16236_CR19","doi-asserted-by":"crossref","unstructured":"Haist, M. et al. Anticoagulation with factor Xa inhibitors is associated with improved overall response and Progression-Free survival in patients with metastatic malignant melanoma receiving immune checkpoint inhibitors-A retrospective, Real-World cohort study. Cancers (Basel). 13(20), 5103 (2021).","DOI":"10.3390\/cancers13205103"},{"issue":"6","key":"16236_CR20","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s12094-020-02515-3","volume":"23","author":"L Gutierrez-Sainz","year":"2021","unstructured":"Gutierrez-Sainz, L. et al. Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. Clin. Transl Oncol. 23 (6), 1245\u20131252 (2021).","journal-title":"Clin. Transl Oncol."},{"issue":"1","key":"16236_CR21","doi-asserted-by":"publisher","first-page":"10225","DOI":"10.1038\/s41598-018-28583-8","volume":"8","author":"L Strobel","year":"2018","unstructured":"Strobel, L. & Johswich, K. O. Anticoagulants impact on innate immune responses and bacterial survival in whole blood models of neisseria meningitidis infection. Sci. Rep. 8 (1), 10225 (2018).","journal-title":"Sci. Rep."},{"issue":"13","key":"16236_CR22","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1158\/1078-0432.CCR-22-2757","volume":"29","author":"F Wei","year":"2023","unstructured":"Wei, F. et al. Anticoagulants enhance molecular and cellular immunotherapy of cancer by improving tumor microcirculation structure and function and redistributing tumor infiltrates. Clin. Cancer Res. 29 (13), 2525\u20132539 (2023).","journal-title":"Clin. Cancer Res."},{"key":"16236_CR23","doi-asserted-by":"crossref","unstructured":"Quan, Y. et al. Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer. J. Immunother Cancer. 11(8), e007080 (2023).","DOI":"10.1136\/jitc-2023-007080"},{"issue":"7","key":"16236_CR24","doi-asserted-by":"publisher","first-page":"e0134259","DOI":"10.1371\/journal.pone.0134259","volume":"10","author":"QY Lean","year":"2015","unstructured":"Lean, Q. Y. et al. Orally administered Enoxaparin ameliorates acute colitis by reducing Macrophage-Associated inflammatory responses. PLoS One. 10 (7), e0134259 (2015).","journal-title":"PLoS One"},{"issue":"11","key":"16236_CR25","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75 (11), 2139\u20132145 (2015).","journal-title":"Cancer Res."},{"issue":"12","key":"16236_CR26","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","volume":"18","author":"GH Lyman","year":"2013","unstructured":"Lyman, G. H., Eckert, L., Wang, Y., Wang, H. & Cohen, A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist 18 (12), 1321\u20131329 (2013).","journal-title":"Oncologist"},{"issue":"7","key":"16236_CR27","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ajh.25494","volume":"94","author":"DE Angelini","year":"2019","unstructured":"Angelini, D. E., Radivoyevitch, T., McCrae, K. R. & Khorana, A. A. Bleeding incidence and risk factors among cancer patients treated with anticoagulation. Am. J. Hematol. 94 (7), 780\u2013785 (2019).","journal-title":"Am. J. Hematol."},{"issue":"2","key":"16236_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.21037\/apm.2017.11.01","volume":"7","author":"C Johnstone","year":"2018","unstructured":"Johnstone, C. & Rich, S. E. Bleeding in cancer patients and its treatment: a review. Ann. Palliat. Med. 7 (2), 265\u2013273 (2018).","journal-title":"Ann. Palliat. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16236-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16236-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T09:31:04Z","timestamp":1757410264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16236-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16236"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16236-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30606"}}